Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Search


Order results by:     
 
Issue Title
 
Vol 16, No 5 (2020) The CES1 Gene rs2244613 Minor Allele Impact on the Safety Profile of Dabigatran Etexilate: Meta-Analysis Abstract  similar documents
S. P. Abdullaev, K. B. Mirzaev, P. O. Bochkov, I. N. Sychev, D. A. Sychev
"... influence on the equilibrium concentration and the risk of bleeding during dabigatran taking. Material ..."
 
Vol 7, No 1 (2011) ANTITHROMBOTIC THERAPY IN ATRIAL FIBRILLATION: NEW DATA AND NEW HORIZONS Abstract  similar documents
M. Yu. Gilyarov, V. A. Sulimov
"... are considered. Special attention are paid to the direct thrombin inhibitors — dabigatran. Possibilities ..."
 
Vol 15, No 2 (2019) Studies of Anticoagulant Therapy in Frail Elderly Patients: Problems of Terminology and Methodology Abstract  similar documents
S. N. Bel'diev, I. V. Medvedeva, D. Yu. Platonov, G. Yu. Trufanova
 
Vol 15, No 2 (2019) Studies of Anticoagulant Therapy in Frail Elderly Patients: Problems of Terminology and Methodology Abstract  similar documents
Sergey N. Bel'diev, Irina V. Medvedeva, Dmitry Yu. Platonov, Galina Yu. Trufanova
 
Vol 18, No 5 (2022) Thrombocytopenia Induced by Direct Oral Anticoagulants: a Clinical Case and Literature Review Abstract  similar documents
B. A. Tatarsky, N. V. Kazennova
"... thrombin blockers (dabigatran) or factor IIa blockers (apixaban, rivaroxaban, edoxaban). According ..."
 
Vol 12, No 5 (2016) Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation Abstract  similar documents
N. A. Novikova, A. N. Volovchenko
"... events in patients with AF. Possibility to perform planned cardioversion while receiving dabigatran has ..."
 
Vol 8, No 6 (2012) HOW TO USE DABIGATRAN IN PATIENTS WITH ATRIAL FIBRILLATION Abstract  similar documents
S. V. Moiseev
"... Dabigatran is the new oral anticoagulant that directly inhibits thrombin (factor IIa). In RE-LY ..."
 
Vol 13, No 5 (2017) DRUG INTERACTIONS OF NEW ORAL ANTICOAGULANTS: INSIDE AND OUTSIDE TABLE CELLS Abstract  similar documents
S. N. Bel'diev, I. V. Medvedeva, D. Yu. Platonov
 
Vol 7, No 6 (2011) DABIGATRAN ETEXILATE FOR PREVENTION OF CARDIOEMBOLIC COMPLICATIONS IN NONVALVULAR ATRIAL FIBRILLATION: HOW TO DO THE INTERVENTION MORE EFFECTIVE AND SAFER Abstract  similar documents
I. S. Yavelov
"... Application of dabigatran etexilate for prevention of cardioembolic complications in nonvalvular ..."
 
Vol 16, No 2 (2020) The Risk of Myocardial Infarction in Patients with Atrial Fibrillation Taking a Direct Thrombin Inhibitor: Myths and Reality Abstract  similar documents
B. A. Tatarsky, N. V. Kazennova, D. A. Napalkov
"... of cohort and observational studies in real clinical practice on the influence of dabigatran etexilate ..."
 
Vol 13, No 5 (2017) Drug interactions of non-vitamin K antagonist oral anticoagulants: inside and outside table cells Abstract  similar documents
Sergey Nikolaevich Bel'diev, Irina Vladimirovna Medvedeva, Dmitry Jur'evich Platonov
 
Vol 17, No 1 (2021) Pharmacokinetics and Pharmacogenetics of Dabigatran Abstract  similar documents
A. V. Savinova, V. S. Dobrodeeva, M. M. Petrova, R. F. Nasyrova, N. A. Shnayder
"... Dabigatran etexilate is a prodrug of dabigatran, a oral direct inhibitor of thrombin ..."
 
Vol 18, No 3 (2022) Clinically Significant Drug Interactions for Direct Oral Anticoagulants: State of the Art Abstract  similar documents
S. R. Gilyarevsky
"... interactions of apixaban, rivaroxaban and dabigatran with the drugs most frequently used in patients ..."
 
Vol 12, No 2 (2016) THE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION IN CLINICAL PRACTICE Abstract  similar documents
S. V. Moiseev
"... (dabigatran), today are increasingly replacing warfarin and other indirect anticoagulants in preventing stroke ..."
 
Vol 12, No 4 (2016) Clinical significance of new oral anticoagulants in the prevention of thromboembolic complications in patients with atrial fibrillation: not all dreams come true Abstract  similar documents
Yu. A. Bunin, S. V. Miklishanskaya
 
Vol 13, No 1 (2017) DATA OF CLINICAL PRACTICE AS A TOOL FOR CHOICE OF DIRECT ORAL ANTICOAGULANT Abstract  similar documents
D. А. Napalkov, A. A. Sokolova, V. V. Fomin
 
Vol 13, No 3 (2017) PHARMACOGENETIC ASPECTS OF NEW ORAL ANTICOAGULANTS APPLICATION Abstract  similar documents
A. V. Kryukov, D. A. Sychev, O. V. Tereshchenko
"... on the pharmacokinetics of these drugs. RE-LY study showed a 15% decrease in trough dabigatran concentration and 27% lower ..."
 
Vol 7, No 5 (2011) ANTITHROMBOTIC THERAPY IN ATRIAL FIBRILLATION: RECENT APPROACHES AND NEAR PERSPECTIVES Abstract  similar documents
Ya. P. Dovgalevskiy, L. E. Kuvshinova, I. V. Graifer, N. V. Furman, P. Ya. Dovgalevskiy
 
Vol 9, No 3 (2013) ANTICOAGULANT THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: DRUG CHOICE AND DOSAGE ADJUSTMENT Abstract  similar documents
E. L. Dolgova, I. M. Sokolov, Yu. G. Shvarts
 
Vol 11, No 3 (2015) ANALYSIS OF THE INFLUENCE OF THROMBOEMBOLIC COMPLICATIONS PREVENTION WITH ORAL ANTICOAGULANTS ON BUDGET IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION Abstract  similar documents
A. V. Rudakova
"... administration of vitamin K antagonists (warfarin) or the new oral anticoagulants (apixaban, dabigatran ..."
 
Vol 9, No 4 (2013) COMPARISON OF DIRECT COSTS OF DABIGATRAN AND WARFARIN THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION DURING PREPARATION FOR ELECTIVE CARDIOVERSION IN THE REAL CLINICAL PRACTICE Abstract  similar documents
L. E. Kuvshinova, N. V. Furman, P. V. Dolotovskaya, Ya. P. Dovgalevsky
"... Aim. To compare direct medical costs of dabigatran and warfarin therapy in patients with non ..."
 
Vol 9, No 4 (2013) COMPARATIVE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS Abstract  similar documents
V. A. Sulimov, D. A. Napalkov, A. A. Sokolova
 
Vol 10, No 4 (2014) NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY Abstract  similar documents
D. A. Napalkov, A. A. Sokolova
"... dabigatran, rivaroxaban and apixaban) is presented from the standpoint of safety. The safety profile ..."
 
Vol 16, No 1 (2020) Control Of Anticoagulation Therapy in Atrial Fibrillation (COAT-AF Study) in Real Clinical Practice Abstract  similar documents
A. A. Zarudsky, A. A. Gavrilova, Т. S. Filinichenko
 
Vol 9, No 5 (2013) PRACTICAL APPLICATION OF DABIGATRAN ETEXILATE FOR STROKE PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION Abstract  similar documents
E. D. Kosmacheva, S. G. Kanorskiy, A. A. Kastanayan, N. V. Haylo, D. B. Goltyapin, E. A. Lipnitskaya, M. E. Statsenko
"... dabigatran etexilate, in the stroke prevention in patients with atrial fibrillation are considered. Factors ..."
 
Vol 16, No 5 (2020) New Pharmacogenetic Markers to Predict the Risk of Bleeding During Taking of Direct Oral Anticoagulants Abstract  PDF (Eng)  similar documents
K. B. Mirzaev, D. V. Ivashchenko, I. V. Volodin, E. A. Grishina, K. A. Akmalova, A. A. Kachanova, A. I. Skripka, R. M. Minnigulov, T. E. Morozova, O. A. Baturina, A. N. Levanov, T. V. Shelekhova, A. I. Kalinkin, D. A. Napalkov, A. A. Sokolova, D. A. Andreev, I. N. Sychev, P. O. Bochkov, D. A. Sychev
"... and dabigatran for different indications: atrial fibrillation, endoprosthesis of large joints of lower limbs ..."
 
Vol 17, No 1 (2021) Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Renal Dysfunction Abstract  similar documents
Z. D. Kobalava, A. A. Shavarov, M. V. Vatsik-Gorodetskaya
 
Vol 17, No 2 (2021) Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation in Real Clinical Practice: in Appropriate Dose Reductions Abstract  similar documents
V. A. Ionin, O. I. Bliznuk, E. I. Baranova, E. V. Shlyakhto
"... : rivaroxaban - 180/384 (46,9%) patients, dabigatran etexilate - 110/384 (28,6%) patients, apixaban - 94/384 (24 ..."
 
Vol 15, No 5 (2019) Rivaroxaban-Associated Hepatotoxicity: a Clinical Case and Literature Review Abstract  similar documents
B. A. Tatarsky, N. V. Kazennova, D. A. Napalkov
 
Vol 12, No 5 (2016) Features of Modern Anticoagulant Therapy in Patients with Nonvalvular Atrial Fibrillation and Chronic Kidney Disease Abstract  similar documents
I. S. Daabul, A. A. Sokolova, D. A. Napalkov
 
Vol 13, No 6 (2017) PREDICTORS OF THE RISK OF HEMORRHAGIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION RECEIVING LONGTERM THERAPY WITH DIRECT ORAL ANTICOAGULANTS Abstract  similar documents
A. А. Sokolova, A. V. Zhilenko, I. L. Tsarev,, D. A. Napalkov, V. V. Fomin
"... and methods. 117 patients receiving DOAC (direct thrombin inhibitors – dabigatran, and Xa factor inhibitors ..."
 
Vol 11, No 1 (2015) PHARMACOECONOMIC ASPECTS OF APIXABAN FOR PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION Abstract  similar documents
A. V. Rudakova
"... , rivaroxaban and dabigatran. Along with clinical efficacy and safety profile one of the main characteristics ..."
 
Vol 15, No 6 (2019) Safety of Non-Vitamin K Oral Anticoagulants in Elderly Patients with Atrial Fibrillation Abstract  similar documents
M. A. Gabitova, P. M. Krupenin, A. A. Sokolova, D. A. Napalkov, V. V. Fomin
"... of age with confirmed AF, receiving dabigatran in a reduced dosage, apixaban or rivaroxaban in full ..."
 
Vol 16, No 1 (2020) The Efficacy, Safety and Adherence to Treatment when New Anticoagulants Taking in Over 75 Years Old Patients with Atrial Fibrillation Abstract  similar documents
A. N. Turov, S. V. Panfilov, О. V. Tschiglinzeva
"... of the observation study was from 12 to 42 (26.9±4.9) months. Dabigatran was taken in 38.5% (n=166) of patients ..."
 
Vol 9, No 5 (2013) APPLICATIONS OF PHARMACOGENETIC TESTING FOR PERSONALIZATION OF THERAPY WITH ORAL ANTICOAGULANTS IN RUSSIA Abstract  similar documents
D. A. Sychev, R. E. Kazakov, V. A. Otdelenov, A. B. Prokofiev
 
Vol 8, No 1 (2012) PHARMACOECONOMIC EVALUATION OF DABIGATRAN VS WARFARIN IN CARDIOVASCULAR EVENTS PREVENTION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION Abstract  similar documents
Yu. B. Belousov, V. Yu. Mareev, I. S. Yavelov, D. Yu. Belousov
"... According to recent guidelines, oral dabigatran etexilate is indicated for stroke and systemic ..."
 
Vol 14, No 3 (2018) THROMBOSIS OF LEFT ATRIAL APPENDAGE DURING THERAPY WITH DIRECT ORAL ANTICOAGULANT. CLINICAL CASE Abstract  similar documents
I. S. Daaboul, S. Yu. Koroleva, A. A. Kudrjavtseva, A. A. Sokolova, D. A. Napalkov, V. V. Fomin
"... , it was decided to replace apixaban with another direct oral anticoagulant – dabigatran 150 mg bid for a period ..."
 
Vol 14, No 4 (2018) Hepatotoxicity of New Oral Anticoagulants Abstract  similar documents
A. R. Kasimova, A. V. Philippova (Guryanova), A. S. Kolbin
 
Vol 16, No 6 (2020) An Elderly Comorbid Patient with Atrial Fibrillation: What is Important to Know and What Should be Considered When Prescribing Anticoagulants? Abstract  similar documents
T. V. Pavlova
 
Vol 19, No 3 (2023) Current insights into the possible role of laboratory monitoring of effectiveness and safety of direct oral anticoagulants Abstract  similar documents
S. R. Gilyarevsky, N. K. Vereina, M. V. Golshmid
 
Vol 18, No 6 (2022) Left Ventricular Thrombosis: Current Perspective and Use of Direct Oral Anticoagulants Abstract  similar documents
A. D. Aga, A. A. Sokolova, D. A. Napalkov
 
1 - 41 of 41 Items

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default articles containing any term in the query are returned (i.e., OR is implied)
  • Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
  • Combine multiple words with AND to find articles containing all terms; e.g., education AND research
  • Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
  • Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)